We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
QuidelOrtho (QDEL) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Read MoreHide Full Article
QuidelOrtho (QDEL - Free Report) reported $744 million in revenue for the quarter ended September 2023, representing a year-over-year decline of 5.1%. EPS of $0.90 for the same period compares to $1.85 a year ago.
The reported revenue represents a surprise of +14.25% over the Zacks Consensus Estimate of $651.23 million. With the consensus EPS estimate being $0.45, the EPS surprise was +100.00%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how QuidelOrtho performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Net Revenues by product- Molecular Diagnostic Solutions: $5.60 million compared to the $8.93 million average estimate based on three analysts.
Net Revenues by product- Point-of-Care: $233.10 million compared to the $152.14 million average estimate based on three analysts.
Net Revenues by product- Transfusion Medicine: $163.90 million versus $151.50 million estimated by three analysts on average.
Net Revenues by product- Labs: $341.40 million versus $332.61 million estimated by three analysts on average.
Shares of QuidelOrtho have returned -16.3% over the past month versus the Zacks S&P 500 composite's -2.2% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
QuidelOrtho (QDEL) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
QuidelOrtho (QDEL - Free Report) reported $744 million in revenue for the quarter ended September 2023, representing a year-over-year decline of 5.1%. EPS of $0.90 for the same period compares to $1.85 a year ago.
The reported revenue represents a surprise of +14.25% over the Zacks Consensus Estimate of $651.23 million. With the consensus EPS estimate being $0.45, the EPS surprise was +100.00%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how QuidelOrtho performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Revenues by product- Molecular Diagnostic Solutions: $5.60 million compared to the $8.93 million average estimate based on three analysts.
- Net Revenues by product- Point-of-Care: $233.10 million compared to the $152.14 million average estimate based on three analysts.
- Net Revenues by product- Transfusion Medicine: $163.90 million versus $151.50 million estimated by three analysts on average.
- Net Revenues by product- Labs: $341.40 million versus $332.61 million estimated by three analysts on average.
View all Key Company Metrics for QuidelOrtho here>>>Shares of QuidelOrtho have returned -16.3% over the past month versus the Zacks S&P 500 composite's -2.2% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.